Helen M. Thackray, SVP Clinical Development, CMO at GLYCOMIMETICS INC (GLYC), sold 2,000 shares at $12.14 ($24K) on 2017-05-19, disclosed to the SEC on 2017-05-22.
Scheduled sale ($24k) by SVP Clinical Development, CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| BCRX | SELL | 2022-12-19 | $34K | — | Filing → |
| BCRX | SELL | 2022-04-04 | $123K | — | Filing → |
| GLYC | SELL | 2017-12-12 | $30K | — | Filing → |